The effect of fluoride on the scavenging of organophosphates by human butyrylcholinesterase in buffer solutions and human plasma

Toxicology and Applied Pharmacology

Volumn 194, Issue 1, 2004, Pages 90-99

  Ashani, Yacov ^a   Segev, Omri ^a   Balan, Ayala ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Fluoride; Human butyrylcholinesterase; Inhibition; Kinetics; Organophosphates

Indexed keywords

BUFFER; CHOLINESTERASE; DYFLOS; ECOTHIOPATE; ENZYME INHIBITOR; FLUORIDE; FLUORINE; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; ORGANOPHOSPHATE; PARAOXON; SARIN; SCAVENGER; SOMAN;

ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; KINETICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH; PHOSPHORYLATION; PLASMA;

EID: 0346059397     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2003.09.007     Document Type: Article

References (31)

1. Allon N., Raveh L., Gilat E., Cohen E., Grunwald J., Ashani Y. Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase. Toxicol. Sci. 43:1998;121-128.
2. Ashani Y. Prospective of human butyrylcholinesterases as detoxifying antidote and potential regulator of controlled-release drugs. Drug Dev. Res. 50:2000;298-308.
3. Ashani Y., Shapira S., Levy D., Wolfe A.D., Doctor B.P., Raveh L. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem. Pharmacol. 41:1991;37-41.
4. Asthana S., Greig N.H., Hegedus L., Holloway H.H., Raffaele K.C., Schapiro M.B., Soncrant T.T. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clin. Pharmacol. Ther. 58:1995;299-309.
5. Bond A.M., Hefter G. Critical survey of stability constants and related thermodynamic data of fluoride complexes in aqueous solutions. IUPAC Chemical Data Series No. 27. 1980;Pergamon, Oxford.
6. Brandeis R., Raveh L., Grunwald J., Cohen E., Ashani Y. Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats. Pharmacol., Biochem. Behav. 46:1993;889-896.
7. Cimasoni G. Inhibition of cholinesterases by fluoride in vitro. Biochem. J. 99:1966;133-137.
8. Darreh-Shori T., Almkvist O., Guan Z.Z., Garlind A., Strandberg B., Svensson A.L., Soreq H., Hellstrom-Lindahl E., Nordberg A. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology. 59:2002;563-572.
9. Dixon M. The determination of enzyme inhibitor constants. Biochem. J. 55:1953;170-171.
10. Doctor B.P., Maxwell D.M., Ashani Y., Saxena A., Gordon R.K. New approaches to medical protection against chemical warfare nerve agents. Somani S.M., Romano J.A. Jr. Chemical Warfare Agents: Toxicity at Low levels. 2001;191-214 CRC Press, New York.
11. Ekstrand J., Fejerskov O., Silverstone L.M. Fluoride metabolism. Ekstrand J., Fejerskov O., Silverstone L.M. Fluoride in Dentistry. 1988;150-170 Munksgaard, Copenhagen.
12. Ellman G.L., Courtney K.D., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95.
13. Foldes F.F., Deery A. Protein binding of atracurium and other short-acting neuromuscular blocking agents and their interaction with human cholinesterases. Br. J. Anaesth. 55(Suppl. 1):1983;31S-34S.
14. Gearhart J.M., Jepson G.W., Clewel J.H. III, Andersen M.E., Conolly R.B. Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropylfluorophosphate. Toxicol. Appl. Pharmacol. 106:1990;295-310.
15. Greenspan C.M., Wilson I.B. The effect of fluoride on the reaction of acetylcholinesterase with carbamates. Mol. Pharmacol. 6:1970;266-272.
16. Greenspan C.M., Wilson I.B. The effect of fluoride on the reactions of methanesulfonates with acetylcholinesterase. Mol. Pharmacol. 6:1970;460-467.
17. Grunwald J., Marcus D., Papier Y., Raveh L., Pittel Z., Ashani Y. Large-scale purification and long-term stability of human butyrylcholinesterase: a potential bioscavenger drug. J. Biochem. Biophys. Methods. 34:1997;123-135.
18. Harris H., Whittaker M. Differential inhibition of human serum butyrylcholinesterase with fluoride: recognition of two new phenotypes. Nature. 191:1961;496-498.
19. Heilbronn E. Action of fluoride on cholinesterase. I. On mechanism of inhibition. Acta Chem. Scand. 19:1965;1333-1346.
20. Krupka R.M. Fluoride inhibition of acetylcholinesterase. Mol. Pharmacol. 2:1966;558-569.
21. McDonagh M.S., Whiting P.F., Wilson P.M., Sutton A.J., Chestnutt I., Cooper J., Misso K., Bradley M., Treasure E., Kleijnen J. Systematic review of water fluoridation. Br. Med. J. 321:2000;855-859.
22. Morel N., Bon S., Greenblat H.M., Van Belle D., Wodak S.J., Sussman J.L., Massoulie J., Silman I. Effect of mutation within the peripheral anionic site on the stability of acetylcholinesterase. Mol. Pharmacol. 55:1999;982-992.
23. Muller T.C., Rocha J.B., Morsh V.M., Neis R.T., Schetinger M.R. Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity. Biochim. Biophys. Acta. 1587:2002;92-98.
24. Murray J.M., Trinick T.R. Plasma fluoride concentrations during and after prolonged anesthesia: a comparison of halothane and isoflurane. Anesth. Analg. 74:1992;236-240.
25. Page J.D., Wilson I.B. The inhibition of acetylcholinesterase by arsenite and fluoride. Arch. Biochem. Biophys. 226:1983;492-497.
26. Page J.D., Wilson I.B., Silman I. Butyrylcholinesterase: inhibition by arsenite, fluoride, and other ligands, cooperativity in binding. Mol. Pharmacol. 27:1985;437-443.
27. Payne C.S., Saeed M., Wolfe A.D. Ligand stabilization of cholinesterases. Biochim. Biophys. Acta. 999:1989;46-51.
28. Raveh L., Grunwald J., Marcus D., Papier Y., Cohen E., Ashani Y. Human butyrylcholinesterases as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem. Pharmacol. 45:1993;2465-2474.
29. Raveh L., Grauer E., Grunwald J., Cohen E., Ashani Y. The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterases. Toxicol. Appl. Pharmacol. 145:1997;43-53.
30. Sussman J.L., Harel M., Frolow F., Oefner C., Goldman A., Toker L., Silman I. Atomic structure of acetylcholinesterase from Torpedo Californica: a prototype acetylcholine-binding protein. Science. 253:1991;872-879.
31. Thomsen T., Kewitz H., Pleul O. Estimation of cholinesterase activity (EC 3.1.1.7; 3.1.1.8) in undiluted plasma and erythrocytes as a tool for measuring in vivo effects of reversible inhibitors. J. Clin. Chem. Clin. Biochem. 26:1988;469-475.